rifaximin

(redirected from Xifaxan)
Also found in: Medical.
Related to Xifaxan: Rifaximin
Translations

rifaximin

n rifaximina
References in periodicals archive ?
XIFAXAN GROWTH IMPROVING: Gilbert also highlighted that Xifaxan is Valeant's largest product and an important growth driver.
Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora.
Pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX) reported on Monday an increase in its sales force by nearly 40% to capture untapped primary care OIC market for its key products, Xifaxan (rifaximin) and RELISTOR (methylnaltrexone bromide) with immediate effect.
It's a gross looking sign, not unlike the green phlegm creature in the ads for Musinex or the bowels constantly looking for the toilet in the Xifaxan ad.
Former Chief Financial Officer Howard Schiller said he thought that Xifaxan, a gastrointestinal medicine that came with Valeant's acquisition last year of its maker Salix, may have stayed at the same price.
Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan and antidepressants are used off-label for the management of IBS patients in Italy.
Antidepressants and antibiotics (mainly Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan [rifaximin]), are also commonly used off-label to treat IBS.
Xifaxan is considered to have potential in the treatment of irritable bowel syndrome.
notes that the New England Journal of Medicine has published results from the company's two pivotal Phase 3 efficacy and safety studies (TARGET 1 and TARGET 2) of Xifaxan 550 mg tablets for the treatment of irritable bowel syndrome without constipation (Non-C IBS).
Salix Pharmaceuticals Ltd (Morrisville NC) reported a bigger first-quarter loss as it prepared to launch its drug Xifaxan as a treatment for neurological problems associated with liver failure.
Salix Pharmaceuticals, Ltd, Raleigh, NC, announced the US Food and Drug Administration (FDA) has granted marketing approval for Xifaxan 550 mg tablets for reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age or older.
XIFAXAN (rifaximin) is a gut-selective antibiotic with negligible systemic absorption (<0.